Andrew Baum
Stock Analyst at Citigroup
(1.65)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PFE Pfizer | Maintains: Neutral | 25 26 | 24.61 | 5.65% | 7 | Aug 6, 2025 | |
BMY Bristol-Myers Squibb | Maintains: Neutral | 51 47 | 45.94 | 2.31% | 10 | Aug 1, 2025 | |
MRK Merck & Co | Downgrades: Neutral | 115 84 | 80.06 | 4.92% | 10 | May 14, 2025 | |
RPRX Royalty Pharma | Maintains: Buy | 60 40 | 36.2 | 10.5% | 2 | Oct 25, 2024 | |
ABBV AbbVie | Maintains: Strong Buy | 170 215 | 198.62 | 8.25% | 11 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 675 895 | 635.48 | 40.84% | 7 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 5 10 | 8.52 | 17.37% | 3 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Jul 5, 2017 |